CD95 pp 41-48 | Cite as

Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition

  • Melissa Thomas
  • Patrick Legembre
Part of the Methods in Molecular Biology book series (MIMB, volume 1557)


Distribution of the death receptor CD95 into lipid rafts (aggregation) and/or its internalization may contribute to the implementation of the apoptotic signal at the detriment of the non-apoptotic signaling pathway [1–6]. Also CD95 can form different protein complexes via dynamic protein–protein interactions (PPIs) according to its interaction with soluble or transmembrane CD95L. Therefore, spatiotemporal identification of these PPIs is pivotal to anticipate the signaling pathway implemented in cells stimulated with different forms of CD95L. Also, many disorders result from dysfunctions in terms of PPI subcellular distribution and/or their intensity, rendering evaluation of these features crucial to better understand pathogenesis.

In situ proximity ligation assay (PLA) is a methodology that offers the possibility to identify PPIs and to determine where these PPIs occur in subcellular location (Fig. 1). Moreover, based on imaging, this method allows a quantification of PPIs at the cellular level and with a higher specificity than classical immunofluorescence assays. We here describe PLA used to confirm CD95/FADD interaction, a protocol that may serve to highlight other CD95 partners.

Key words

CD95 Death inducing signaling complex FADD Protein–protein interaction Proximity ligation assay 


  1. 1.
    Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME (2002) Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 22(1):207–220CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, Conchonaud F, Marguet D, He HT, Hueber AO (2007) Palmitoylation is required for efficient Fas cell death signaling. EMBO J 26(1):209–220CrossRefPubMedGoogle Scholar
  3. 3.
    Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schutze S, Peter ME, Chan AC (2006) The role of receptor internalization in CD95 signaling. EMBO J 25(5):1009–1023CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Legembre P, Beneteau M, Daburon S, Moreau JF, Taupin JL (2003) Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J Immunol 171(11):5659–5662CrossRefPubMedGoogle Scholar
  5. 5.
    Legembre P, Daburon S, Moreau P, Ichas F, de Giorgi F, Moreau JF, Taupin JL (2005) Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment. Mol Cell Biol 25(15):6811–6820CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Legembre P, Moreau P, Daburon S, Moreau JF, Taupin JL (2002) Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell Death Differ 9(3):329–339CrossRefPubMedGoogle Scholar
  7. 7.
    Tauzin S, Debure L, Moreau JF, Legembre P (2012) CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cell Mol Life Sci 69(8):1261–1277CrossRefPubMedGoogle Scholar
  8. 8.
    Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Leveque J, Jezequel P, Campion L, Campone M, Ducret T, Macgrogan G, Debure L, Collette Y, Vacher P, Legembre P (2013) CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 73(22):6711–6721CrossRefPubMedGoogle Scholar
  9. 9.
    Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, Blanco P, Le Seyec J, Ducret T, Counillon L, Moreau JF, Hofman P, Vacher P, Legembre P (2011) The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 9(6):e1001090CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gustafsdottir SM, Schallmeiner E, Fredriksson S, Gullberg M, Soderberg O, Jarvius M, Jarvius J, Howell M, Landegren U (2005) Proximity ligation assays for sensitive and specific protein analyses. Anal Biochem 345(1):2–9CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Centre Eugène MarquisRennesFrance
  2. 2.INSERM ERL440-OSSEquipe Labellisée Ligue Contre Le CancerRennesFrance
  3. 3.Université de Rennes-1RennesFrance

Personalised recommendations